Benlysta
| Chemical Name | belimumab |
| Dosage Form | Injection (subcutaneous; 200 mg/mL); Injection (intravenous; 120 mg, 400 mg) |
| Drug Class | B-lymphocyte stimulator-specific inhibitors |
| System | Multiple |
| Company | GalaxoSmithKline |
| Approval Year | 2011 |
Indication
- For the treatment of patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
- For the treatment of adult patients with active lupus nephritis who are receiving standard therapy.